pembrolizumab,ramucirumab
eli lilly,merck
['sclc', 'ramucirumab', 'nsclc', 's1800a', 'pembro']
it s been refreshing to see colleagues and discuss the data at #asco2022 we are excited to see coverage #ascodailynews of the os benefit for previously treated nsclc with ramucirumab and pembrolizumab in s1800a 
Medical Oncologist, lung cancer, Director, Division of Medical Oncology Associate Director of Clinical Research Cedars-Sinai Cancer